Janssen Faces Mixed Prospects In Immuno Drug IP Suit

By Brian Amaral (August 16, 2016, 11:11 PM EDT) -- A federal judge in Boston on Tuesday gave good news to both Janssen Biotech and Celltrion Healthcare in their dispute over a biosmilar version of Janssen's $4 billion-a-year immunosuppressant drug, saying while he is likely to declare one patent in the suit invalid, he would likely reject challenges to the other....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!